A Preview Of Ares Comml Real Est’s Earnings

Ares Comml Real Est (NYSE:ACRE) is set to give its latest quarterly earnings report on Friday, 2023-11-03. Here’s…

Ares Comml Real Est (NYSE:ACRE) is set to give its latest quarterly earnings report on Friday, 2023-11-03. Here’s what investors need to know before the announcement.

Analysts estimate that Ares Comml Real Est will report an earnings per share (EPS) of $0.21.

Ares Comml Real Est bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Historical Earnings Performance

Last quarter the company beat EPS by $0.07, which was followed by a 2.03% increase in the share price the next day.

Here’s a look at Ares Comml Real Est’s past performance and the resulting price change:

Quarter Q2 2023 Q1 2023 Q4 2022 Q3 2022
EPS Estimate 0.28 0.23 0.33 0.32
EPS Actual 0.35 0.27 0.44 0.39
Price Change % 2.03% 3.94% -2.9% -4.73%

eps graph

Stock Performance

Shares of Ares Comml Real Est were trading at $9.2 as of November 01. Over the last 52-week period, shares are down 20.06%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.

To track all earnings releases for Ares Comml Real Est visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Multi-Banner Cannabis Retailer’s Q3 Revenue Slumps Over 42% YoY But CEO Remains Optimistic

Shiny Health & Wellness Corp. has reported a decrease in sales to CA$ 4.3 million ($3.2m million) for the three months ending October 31, 2023, down from CA$ 7.46m the previous financial year. The decline was attributed to market trends in the Ontario cannabis retail sector throughout the period, the pharmaceutical company said. Shiny Health also closed underperforming adult-use cannabis dispensaries and sold a number of larger stores. The Toronto-based firm recently inked an agreement with Karan S. Holla for his chain of 10 adult-use cannabis retail outlets, Stash & Co. CEO Meris Kott said Shiny Health was gradually building its brand presence in Ontario. The pharma company revealed that it made a CA$ 6m net loss for the quarter, an uptick from the CA$ 1.75m loss in the corresponding period the year before.

TSXV:SNYB